Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Goodwill & Intangibles (2020 - 2026)

InMed Pharmaceuticals has reported Goodwill & Intangibles over the past 5 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 9.56% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 9.56%, while the annual FY2025 figure was $1.6 million, 44.64% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $1.5 million at InMed Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $4.7 million in Q1 2022 and troughed at $1.0 million in Q3 2021.
  • A 5-year average of $2.4 million and a median of $2.0 million in 2022 define the central range for Goodwill & Intangibles.
  • Biggest five-year swings in Goodwill & Intangibles: plummeted 57.65% in 2023 and later skyrocketed 112.51% in 2024.
  • Year by year, Goodwill & Intangibles stood at $4.4 million in 2021, then crashed by 54.18% to $2.0 million in 2022, then surged by 44.43% to $2.9 million in 2023, then crashed by 41.89% to $1.7 million in 2024, then dropped by 9.56% to $1.5 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for INM at $1.5 million in Q4 2025, $2.9 million in Q3 2025, and $1.6 million in Q2 2025.